RxDoctor Payments Data

Stephanie Harris

Psychiatric/Mental Health · Carleton, MINPI 1760137996

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 285 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,639, more than ten times the $212 reported in 2022. Among psychiatric/mental health clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,956in general payments, 2019–2025

Across 285 payments — averaging $20.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$884
  • AbbVie$876
  • Otsuka America Pharmaceutical, Inc.$607
  • Supernus Pharmaceuticals, Inc.$605
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$548
  • Corium, LLC$417
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$5,85198%
  • Education$1042%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,956 in reported general payments places this provider in the 90th percentile of 638 psychiatric/mental health providers in Michigan.

See all psychiatric/mental health providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine22$136,573
VraylarCariprazine Hcl71$116,730
TrintellixVortioxetine Hydrobromide19$17,651
Paliperidone ErPaliperidone17$4,742
Quetiapine Fumarate51$1,409
Trazodone Hcl52$1,388
Oxcarbazepine20$1,243
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine23$1,168
Aripiprazole42$1,153
Buspirone Hcl59$1,092
Duloxetine Hcl30$796
Bupropion XlBupropion Hcl41$778
Mirtazapine30$397
Venlafaxine Hcl ErVenlafaxine Hcl20$346
Propranolol Hcl28$314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$884$136,57322 claims
AbbVieVraylar$876$116,73071 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 638 psychiatric/mental health providers in Michigan.

Other psychiatric/mental health in Carleton

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →